The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Affiliations

¹ The Alfred Hospital, Monash University and Australian Centre for Blood Diseases, Melbourne, Victoria, Australia.
² School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
³ Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia.
⁴ Middlemore Hospital, Auckland, New Zealand.
⁵ St. Vincent's Hospital, Melbourne, Victoria, Australia.
⁶ Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁷ Christchurch Hospital, Christchurch, New Zealand.
⁸ Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
⁹ Epworth Healthcare and Sir Peter MacCallum Department of Oncology University of Melbourne, Parkville, Victoria, Australia.
¹⁰ Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
¹¹ University Hospital Geelong, Geelong, Victoria, Australia.

Joanne L C Tan et al. Br J Haematol. 2023 Jan.

. 2023 Jan;200(2):e17-e21.

doi: 10.1111/bjh.18536. Epub 2022 Nov 2.

¹ The Alfred Hospital, Monash University and Australian Centre for Blood Diseases, Melbourne, Victoria, Australia.
² School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
³ Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia.
⁴ Middlemore Hospital, Auckland, New Zealand.
⁵ St. Vincent's Hospital, Melbourne, Victoria, Australia.
⁶ Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁷ Christchurch Hospital, Christchurch, New Zealand.
⁸ Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
⁹ Epworth Healthcare and Sir Peter MacCallum Department of Oncology University of Melbourne, Parkville, Victoria, Australia.
¹⁰ Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
¹¹ University Hospital Geelong, Geelong, Victoria, Australia.

No abstract available

Keywords: cancer cytogenetics; myeloma; prognostic factors.

References

1. D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406-18.
1. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-9.
1. Kostopoulos I v, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches. Frontiers in Oncology. 2020;10:860.
1. Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, et al. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Med Res Methodol. 2016;16(1):151.
1. Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison SJ, et al. The myeloma landscape in Australia and New Zealand: The first 8 years of the Myeloma and Related Diseases Registry (MRDR). Clin Lymphoma Myeloma Leuk. 2021;21(6):e510-20.